logo
Plus   Neg
Share
Email

Kite And Humanigen Collaborate To Conduct Clinical Study On Relapsed/DLBCL

Kite, a Gilead Company (GILD), and Humanigen Inc. (HGEN) said that they have formed a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta in patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. Kite will act as the sponsor of the study and will be responsible for its conduct.

The study will determine the effect of lenzilumab on the safety of Yescarta.

The company noted that Lenzilumab, alone or in combination with other therapies such as Yescarta, is investigational and has not been approved by the FDA or any regulatory authority for any uses. Efficacy and safety have not yet been established.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. warned that its newly launched titanium Apple Card can be easily damaged if not stored properly. The company advised that the card must be kept away from fabrics like leather and denim as they can cause permanent discoloration. The tech giant has posted a support page that provides instructions to users on how to protect and maintain their Apple Card. Southwire Co. LLC recalled about 3000 units of Garvin pop-up electrical outlet floor box kits for concerns of fire hazard. The company said the electrical receptacles can overheat when in use. Southwire already received three reports of the floor boxes overheating. However, there have been no injuries reported so far. The Pentagon has canceled a billion dollar contract with Boeing Co. for a new ballistic missile interceptor due to technical design problems. The contract was for developing the Redesigned Kill Vehicle or RKV, intended to intercept and shoot down current and future-generation incoming ballistic missiles from North Korea and Iran at extremely high altitudes.
Follow RTT